Please use this identifier to cite or link to this item: http://nopr.niscair.res.in/handle/123456789/13006
Title: Transforming growth factor 2: A predictive marker for breast cancer
Authors: Dave, Heena
Trivedi, Sunil
Shah, Manoj
Shukla, Shilin
Keywords: Breast cancer;mRNA;Prognosis;Serum;Survival;TGF-2
Issue Date: Nov-2011
Publisher: NISCAIR-CSIR, India
Abstract: Dual role of TGF- signaling in breast tumorigenesis as an inhibitor in early stages and promoter in advanced stages has been well established and known as TGF- switch. However, the biological mechanisms needs to be explored. Aim of the present study was to look for the usefulness of TGF-2 as a predictive marker for breast cancer and to offer a better predictability to identify patients likely to benefit from antiTGF- strategies. Circulatory as well as transcript levels of TGF-2 were estimated from 118 pretherapeutic breast cancer patients using ELISA and q-PCR with ddCt method. Multifactorial analysis was performed to correlate the results to clinico-pathological prognosticators and Kaplan-Meier survival analysis with a median follow-up of 49 months was also evaluated. Circulating TGF-2 was similar in control and breast cancer patients. TGF-2 was significantly upregulated in advanced tumors compared to early tumors. An inverse correlation was observed between TGF-2 protein and mRNA; nevertheless both exhibited significant correlations with clinico-pathological prognosticators. Higher expression of TGF-2 mRNA was connected to an early relapse in advanced stage than early stage patients. It is the first report to evaluate circulatory and transcript levels exhibiting TGF- switch and confirming the utility of TGF-2 as an important predictive marker for breast cancer.
Page(s): 879-887
URI: http://hdl.handle.net/123456789/13006
ISSN: 0975-1009 (Online); 0019-5189 (Print)
Appears in Collections:IJEB Vol.49(11) [November 2011]

Files in This Item:
File Description SizeFormat 
IJEB 49(11) 879-887.pdf187.25 kBAdobe PDFView/Open


Items in NOPR are protected by copyright, with all rights reserved, unless otherwise indicated.